⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

October 31, 2016European Respiratory JournalOpen Access

Cardiac safety of extensively drug-resistant tuberculosis regimens including bedaquiline, delamanid and clofazimine

Marina Tadolini Rangjung Dolma Lingtsang Simon Tiberi Martin Enwerem Lia D’Ambrosio Tsetan Dorji Sadutshang Rosella Centis Giovanni Battista Migliori

View Full Paper

Ask AI

Bookmark

Share

Abstract

We read with great interest the comments by R.S. Wallis on our article describing the first case of extensively drug-resistant tuberculosis (XDR-TB) treated with both delamanid and bedaquiline [1], as recommended by the European Respiratory Society hosted TB Consilium experts [2, 3]. First case, concerns and challenges of treatment of severe XDR-TB with both delamanid and bedaquiline

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Tadolini et al. (2016) studied this question.

synapsesocial.com/papers/6a95172ccd304312aafa669b https://doi.org/10.1183/13993003.01552-2016

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquilineOriginal Research · 2016 · 92 citations
2Supporting clinical management of the difficult-to-treat TB cases: the ERS-WHO TB ConsiliumOriginal Research · 2015 · 22 citations
3ERS/WHO Tuberculosis Consilium assistance with extensively drug-resistant tuberculosis management in a child: case study of compassionate delamanid useOriginal Research · 2014 · 99 citations
4Safety and availability of clofazimine in the treatment of multidrug and extensively drug-resistant tuberculosis: analysis of published guidance and meta-analysis of cohort studiesCohort Study · 2014 · 87 citations
5Sterilizing Activities of Novel Combinations Lacking First- and Second-Line Drugs in a Murine Model of TuberculosisEarly-Phase Clinical Trial · 2012 · 156 citations

Faster for less: the new “shorter” regimen for multidrug-resistant tuberculosis2016
A frequent ancestral intronic founder variant in DNAI1 causes primary ciliary dyskinesiaEuropean Respiratory Journal · 2026
Muco-obstructive lung disease exhibits distinct hypoxic and inflammatory airway epithelial gene pathwaysEuropean Respiratory Journal · 2026
Don't discard the supernatant: pleural fluid cfDNA for molecular profiling in lung cancerEuropean Respiratory Journal · 2026
Circulating Activin A, FSTL3 and BMP9 in asymptomatic BMPR2 pathogenic-variant carriersEuropean Respiratory Journal · 2026

EMore from European Respiratory Journal

More from University of Bologna

More from Istituti di Ricovero e Cura a Carattere Scientifico

More from Barts Health NHS Trust

More from Fondazione Salvatore Maugeri

More from Tibetan Delek Hospital